BACKGROUND: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma. PATIENTS AND METHODS: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks. RESULTS: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease. CONCLUSION: Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.
BACKGROUND: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma. PATIENTS AND METHODS: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks. RESULTS: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%-29%) lasting 3-13 months, 22 patients (69%) had a stable disease. CONCLUSION:Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.
Authors: Afshin Teymoortash; Anna Pientka; Carsten Schrader; Markus Tiemann; Jochen A Werner Journal: J Cancer Res Clin Oncol Date: 2005-09-24 Impact factor: 4.553
Authors: Athanassios Argiris; Musie Ghebremichael; Barbara Burtness; Rita S Axelrod; Ronald C Deconti; Arlene A Forastiere Journal: Cancer Date: 2011-01-18 Impact factor: 6.860
Authors: Laura Vidal; Ming S Tsao; Gregory R Pond; Ezra E W Cohen; Roger B Cohen; Eric X Chen; Mark Agulnik; Sebastien Hotte; Eric Winquist; Scott Laurie; D Neil Hayes; James Ho; Janet Dancey; Lillian L Siu Journal: Head Neck Date: 2009-08 Impact factor: 3.147